MedTrace Logo

A Study of the Pharmacokinetics of Three Dosages of Niagen in Healthy Subjects

NCT02191462 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2014-09-09

No results posted yet for this study

Summary

The purpose of this study in to analyse the way in which the body processes Niagen (nicotinamide riboside) in healthy people. Blood and urine samples from subjects who are given a dose of Niagen will be analyzed for metabolites over the 24 hours after taking the dose.

Conditions

  • Pharmacokinetics

Interventions

DIETARY_SUPPLEMENT

Niagen 100mg

DIETARY_SUPPLEMENT

Niagen 300mg

DIETARY_SUPPLEMENT

Niagen 1000mg

Sponsors & Collaborators

  • ChromaDex, Inc.

    collaborator INDUSTRY

  • KGK Science Inc.

    lead INDUSTRY

Principal Investigators

  • Dale Wilson, MD · KGK Science Inc.

Study Design

Allocation
RANDOMIZED
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
30 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2014-08-31
Completion
2014-08-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02191462 on ClinicalTrials.gov